These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8092189)

  • 61. DNA diagnosis with mutation-specific artificial methylation sites: application to rapid screening of delta F508.
    Petty EM; Gold E; Bale AE
    Clin Chem; 1992 Dec; 38(12):2422-5. PubMed ID: 1458578
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A pooling strategy for heterozygote screening of the delta F508 cystic fibrosis mutation.
    Gille C; Grade K; Coutelle C
    Hum Genet; 1991 Jan; 86(3):289-91. PubMed ID: 1997384
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The frequency of the common (delta F508) cystic fibrosis mutation in the Australian population.
    Nelson PV; Carey WF; Morris CP; Pollard AC
    Med J Aust; 1990 Mar; 152(6):328. PubMed ID: 2314338
    [No Abstract]   [Full Text] [Related]  

  • 64. Amplification and detection of specific DNA sequences with fluorescent PCR primers: application to delta F508 mutation in cystic fibrosis.
    Chehab FF; Wall J; Kan YW
    Methods Enzymol; 1992; 216():135-43. PubMed ID: 1479898
    [No Abstract]   [Full Text] [Related]  

  • 65. Screening for defined cystic fibrosis mutations by solid-phase minisequencing.
    Jalanko A; Kere J; Savilahti E; Schwartz M; Syvänen AC; Ranki M; Söderlund H
    Clin Chem; 1992 Jan; 38(1):39-43. PubMed ID: 1733604
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cystic fibrosis: the delta F508 mutation does not lead to an exceptionally severe phenotype. A cohort study.
    Borgo G; Gasparini P; Bonizzato A; Cabrini G; Mastella G; Pignatti PF
    Eur J Pediatr; 1993 Dec; 152(12):1006-11. PubMed ID: 8131801
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Nearly 80% of cystic fibrosis heterozygotes and 64% of couples at risk may be detected through a unique screening of four mutations by ASO reverse dot blot.
    Serre JL; Taillandier A; Mornet E; Simon-Bouy B; Boué J; Boué A
    Genomics; 1991 Dec; 11(4):1149-51. PubMed ID: 1783382
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cystic fibrosis: relationship between clinical status and F508 deletion.
    Campbell PW; Phillips JA; Krishnamani MR; Maness KJ; Hazinski TA
    J Pediatr; 1991 Feb; 118(2):239-41. PubMed ID: 1993951
    [No Abstract]   [Full Text] [Related]  

  • 69. Allelic discrimination by nick-translation PCR with fluorogenic probes.
    Lee LG; Connell CR; Bloch W
    Nucleic Acids Res; 1993 Aug; 21(16):3761-6. PubMed ID: 8367293
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Preimplantation diagnosis of delta F508 mutation of mucoviscidosis in transgenic mice].
    Ji YZ; Nicolas JC; Marechal V; Desire N; Pavirani A; Milliez J
    Presse Med; 1995 Sep; 24(26):1193-7. PubMed ID: 7567845
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Detecting multiple cystic fibrosis mutations by polymerase chain reaction-mediated site-directed mutagenesis.
    Friedman KJ; Highsmith WE; Silverman LM
    Clin Chem; 1991 May; 37(5):753-5. PubMed ID: 2032331
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Abnormal distribution of cystic fibrosis delta F508 allele in adults with chronic bronchial hypersecretion.
    Dumur V; Lafitte JJ; Gervais R; Debaecker D; Kesteloot M; Lalau G; Roussel P
    Lancet; 1990 Jun; 335(8701):1340. PubMed ID: 1971393
    [No Abstract]   [Full Text] [Related]  

  • 73. Compound heterozygosity for delta F508 and F508C: a cautionary note on the molecular diagnosis of cystic fibrosis.
    Dufourcq R; Vuillaumier S; Pascaud O; Guidal C; Oury JF; Elion J; Denamur E
    Prenat Diagn; 1994 Dec; 14(12):1176-7. PubMed ID: 7899288
    [No Abstract]   [Full Text] [Related]  

  • 74. Deletion delta F508 and clinical expression of cystic fibrosis-related liver disease.
    De Arce M; O'Brien S; Hegarty J; O'Mahoney SM; Cashman SM; Martinez A; Delgado M; FitzGerald MX
    Clin Genet; 1992 Nov; 42(5):271-2. PubMed ID: 1486703
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cystic fibrosis deletion mutation detected by PCR-mediated site-directed mutagenesis.
    Friedman KJ; Highsmith WE; Prior TW; Perry TR; Silverman LM
    Clin Chem; 1990 Apr; 36(4):695-6. PubMed ID: 2323051
    [No Abstract]   [Full Text] [Related]  

  • 76. Development and evaluation of a simplified dot-blot method for detecting the delta F508 mutation in cystic fibrosis.
    Skogerboe KJ; West SF; Murillo MD; Tait JF
    Clin Chem; 1990 Nov; 36(11):1984-6. PubMed ID: 2242584
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Detection of delta F508 deletion by amplification refractory mutation system.
    Newton CR; Schwarz M; Summers C; Heptinstall LE; Graham A; Smith JC; Super M; Markham AF
    Lancet; 1990 May; 335(8699):1217-9. PubMed ID: 1971056
    [No Abstract]   [Full Text] [Related]  

  • 78. Ancient DNA analysis of the delta F508 mutation.
    Bramanti B; Hummel S; Chiarelli B; Herrmann B
    Hum Biol; 2003 Feb; 75(1):105-15. PubMed ID: 12713151
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Capillary electrophoresis in polymer networks for analysis of PCR products: detection of delta F508 mutation in cystic fibrosis.
    Gelfi C; Righetti PG; Brancolini V; Cremonesi L; Ferrari M
    Clin Chem; 1994 Aug; 40(8):1603-5. PubMed ID: 8045012
    [No Abstract]   [Full Text] [Related]  

  • 80. Analysis of delta F508 does not confirm a previously reported recombination in a cystic fibrosis family.
    Devoto M; Ronchetto P; Romano L; Romeo G
    Am J Hum Genet; 1990 May; 46(5):1004-5. PubMed ID: 1971140
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.